All In MedTech

FDA Clearance Tracker · P130018

PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Nov 24, 2015 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Nov 24, 2015

Approved

Time to decision

890 days

Received Jun 17, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P130018
Device name
PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN
Applicant location
Plymouth, MN
Received
Jun 17, 2013
Decided
Nov 24, 2015
Decision
Approved
Supplements
6 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 876.5280

Every decision under product code EZY

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN. THIS DEVICE IS INDICATED FOR THE TREATMENT OF ADULT MEN WHO HAVE STRESS INCONTINENCE ARISING FROM INTRINSIC SPHINCTER DEFICIENCY OF AT LEAST TWELVE MONTHS DURATION FOLLOWING RADICAL PROSTATECTOMY OR TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) AND WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE THERAPY.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code EZY. The earliest in FDA's data is P000053, decided Jun 14, 2001.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Uromedica, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.